Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

An open-label pilot study of alefacept for the treatment of pyoderma gangrenosum.

Foss CE, Clark AR, Inabinet R, Camacho F, Jorizzo JL.

J Eur Acad Dermatol Venereol. 2008 Aug;22(8):943-9. doi: 10.1111/j.1468-3083.2008.02680.x. Epub 2008 Apr 1.

PMID:
18384543
2.

Clinical effectiveness and safety experience with alefacept in the treatment of patients with moderate-to-severe chronic plaque psoriasis in Taiwan: results of an open-label, single-arm, multicentre pilot study.

Huang PH, Liao YH, Wei CC, Tseng YH, Ho JC, Tsai TF.

J Eur Acad Dermatol Venereol. 2008 Aug;22(8):923-30. doi: 10.1111/j.1468-3083.2007.02575.x. Epub 2008 Feb 27.

PMID:
18312328
3.

Alefacept for moderate to severe atopic dermatitis: a pilot study in adults.

Moul DK, Routhouska SB, Robinson MR, Korman NJ.

J Am Acad Dermatol. 2008 Jun;58(6):984-9. doi: 10.1016/j.jaad.2008.02.007. Epub 2008 Apr 18.

PMID:
18395294
4.

A randomized controlled study of combination therapy with alefacept and narrow band UVB phototherapy (UVB) for moderate to severe psoriasis: efficacy, onset, and duration of response.

Lui H, Gulliver W, Tan J, Hong CH, Hull P, Shear NH, Paradiso-Hardy F, Bissonette R.

J Drugs Dermatol. 2012 Aug;11(8):929-37.

PMID:
22859237
5.

Alefacept for erosive lichen planus: a case series.

Chang AL, Badger J, Rehmus W, Kimball AB.

J Drugs Dermatol. 2008 Apr;7(4):379-83.

PMID:
18459520
6.

Alefacept with methotrexate for treatment of psoriatic arthritis: open-label extension of a randomized, double-blind, placebo-controlled study.

Mease PJ, Reich K; Alefacept in Psoriatic Arthritis Study Group.

J Am Acad Dermatol. 2009 Mar;60(3):402-11. doi: 10.1016/j.jaad.2008.09.050. Epub 2008 Nov 25. Erratum in: J Am Acad Dermatol. 2009 Sep;61(3):507.

PMID:
19028407
7.

Failure of alefacept in the treatment of vitiligo.

Bin Dayel S, AlGhamdi K.

J Drugs Dermatol. 2013 Feb;12(2):159-61.

PMID:
23377387
8.

Psoriasis responds to intralesional injections of alefacept and may predict systemic response to intramuscular alefacept: interim results of a single-arm, open-label study.

Gattu S, Busse K, Bhutani T, Chiang C, Nguyen T, Becker E, Koo JY.

J Dermatolog Treat. 2012 Apr;23(2):103-8. doi: 10.3109/09546634.2010.500323. Epub 2011 Jan 22.

PMID:
21254875
9.

An open-label study of alefacept plus ultraviolet B light as combination therapy for chronic plaque psoriasis.

Ortonne JP, Khemis A, Koo JY, Choi J.

J Eur Acad Dermatol Venereol. 2005 Sep;19(5):556-63.

PMID:
16164708
10.

Intralesional injections of alefacept may predict systemic response to intramuscular alefacept: results from a pilot study.

Bhutani T, Kamangar F, Zitelli K, Chiang C, Gattu S, Nguyen T, Becker E, Koo J.

J Dermatolog Treat. 2013 Oct;24(5):348-50. doi: 10.3109/09546634.2012.672712. Epub 2012 Jun 5.

PMID:
22506829
11.

An open-label pilot study of apremilast for the treatment of moderate to severe lichen planus: a case series.

Paul J, Foss CE, Hirano SA, Cunningham TD, Pariser DM.

J Am Acad Dermatol. 2013 Feb;68(2):255-61. doi: 10.1016/j.jaad.2012.07.014. Epub 2012 Aug 19.

PMID:
22910104
12.

Treatment of moderate-to-severe psoriasis with alefacept for up to one year: a case series.

Shah A, O'Neill J, Feldman SR.

J Drugs Dermatol. 2010 Dec;9(12):1491-4.

PMID:
21120256
13.

Alefacept revisited: Our 3-year clinical experience in 200 patients with chronic plaque psoriasis.

Perlmutter A, Cather J, Franks B, Jaracz E, Menter A.

J Am Acad Dermatol. 2008 Jan;58(1):116-24. Epub 2007 Nov 12.

PMID:
17997502
14.

Open label trial of alefacept in palmoplantar pustular psoriasis.

Carr D, Tusa MG, Carroll CL, Pearce DJ, Camacho F, Kaur M, Cook C, Willard J, McCarty A, Fleischer AB Jr, Liu CM, Goffe BS, Feldman SR.

J Dermatolog Treat. 2008;19(2):97-100.

PMID:
18512272
15.

UK Dermatology Clinical Trials Network's STOP GAP trial (a multicentre trial of prednisolone versus ciclosporin for pyoderma gangrenosum): protocol for a randomised controlled trial.

Craig FF, Thomas KS, Mitchell EJ, Williams HC, Norrie J, Mason JM, Ormerod AD; UK Dermatology Clinical Trials Network’s STOP GAP Trial Team.

Trials. 2012 Apr 28;13:51.

16.

Canakinumab in adults with steroid-refractory pyoderma gangrenosum.

Kolios AG, Maul JT, Meier B, Kerl K, Traidl-Hoffmann C, Hertl M, Zillikens D, Röcken M, Ring J, Facchiano A, Mondino C, Yawalkar N, Contassot E, Navarini AA, French LE.

Br J Dermatol. 2015 Nov;173(5):1216-23. doi: 10.1111/bjd.14037. Epub 2015 Oct 16.

17.

The safety profile and sustained remission associated with response to multiple courses of intramuscular alefacept for treatment of chronic plaque psoriasis.

Roberts JL, Ortonne JP, Tan JK, Jaracz E, Frankel E; Alefacept Clinical Study Group.

J Am Acad Dermatol. 2010 Jun;62(6):968-78. doi: 10.1016/j.jaad.2009.07.032. Epub 2010 Apr 14.

PMID:
20392521
18.

The safety and efficacy of high-dose alefacept compared with a loading dose of alefacept in patients with chronic plaque psoriasis.

Cafardi JA, Cantrell W, Wang W, Elmets CA, Elewski BE.

Skinmed. 2008 Mar-Apr;7(2):67-72.

PMID:
18327010
19.

Alefacept.

Frampton J, Wagstaff A.

Am J Clin Dermatol. 2003;4(4):277-86; discussion 287. Review.

PMID:
12680805
20.

A multicenter, open-label study of repeat courses of intramuscular alefacept in combination with other psoriasis therapies in patients with chronic plaque psoriasis.

Krueger GG, Gottlieb AB, Sterry W, Korman N, Van De Kerkhof P.

J Dermatolog Treat. 2008;19(3):146-55. doi: 10.1080/09546630701846103.

PMID:
18569270

Supplemental Content

Support Center